Telomir Pharmaceuticals, Inc. (TELO) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2025)

-$10.4M

Total Assets (FY2025)

$7.3M

Total Equity (FY2025)

$5.9M

Cash Flows from Operating Activities (FY2025)

-$3.7M

Source: Telomir Pharmaceuticals, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.